Larsucosterol sodium is under clinical development by DURECT and currently in Phase II for Alcoholic Hepatitis. According to GlobalData, Phase II drugs for Alcoholic Hepatitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Larsucosterol sodium LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Larsucosterol sodium overview
DUR-928 (DV-928) is under development for the treatment of alcoholic hepatitis, nonalcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), alcoholic fatty liver disease (AFLD), chronic kidney disease and acute kidney injury (AKI). It is a small molecule and new chemical entity (NCE). The drug candidate is formulated as both solution and suspension and is administered through oral, intralesional, intramuscular injection and topical routes. The drug candidate is a sulfated oxysterol. It acts by targeting DNMTs, DNMT-1, 3a and 3b.
It was under development for primary sclerosing cholangitis (PSC) and for mild to moderate plaque psoriasis and inflammatory skin conditions like atopic dermatitis. It was also under development for the treatment of COVID-19 patients with acute pneumonia, lung injury, liver or kidney injury.
DURECT overview
DURECT is a biopharmaceutical company that focuses on the research and development of new chemical entities for the treatment of acute organ injury and chronic liver diseases based on its endogenous epigenetic regulator program. The company’s major product pipeline comprises DUR-928, indicated for the treatment of alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, indicated to treat post-operative pain; and Oradur, indicated for chronic pain and attention deficit hyperactivity disorders. DURECT also manufactures and sells osmotic pumps for laboratory research; and offers standard and custom biodegradable polymers and excipients for customers in pharmaceutical and medical device industry. The company operates in the US, Europe, Japan and other countries. DURECT is headquartered in Cupertino, California, the US.
For a complete picture of Larsucosterol sodium’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
